Wednesday, July 18, 2018
 
 
Company News: Page (1) of 1 - 07/12/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
St. Louis Jury Returns $4.69 Billion Verdict in First Trial Linking Baby Powder, Asbestos and Ovarian Cancer
 
(July 12, 2018)

ST. LOUIS, July 12, 2018 /PRNewswire/ -- A jury has awarded $4.69 billion to 22 women and their families who alleged that decades of daily use of Johnson & Johnson's (NYSE: JNJ) asbestos-laden talcum powder products caused their ovarian cancer. 

The six-man, six-woman jury in Judge Rex M. Burlison's 22nd Judicial Circuit Court in St. Louis heard six weeks of testimony and deliberated eight hours before returning the verdict. The jury award includes $550 million in compensatory damages and $4.14 billion in punitive damages against the company.

While there have been other trials in which juries have determined that talc products contained asbestos and caused mesothelioma cancer, this case marks the first talc/asbestos-induced ovarian cancer verdict in the United States. Jurors heard evidence that Johnson & Johnson's Baby Powder and Shower to Shower products have been laced with asbestos for decades, in spite of the representations J&J made to the FDA and others.



Mark Lanier, lead trial counsel for the women and their families, introduced evidence from scientific experts to explain how asbestos, a well-known carcinogen, is intermingled with the mineral talc. Talc is the primary ingredient in Johnson's Baby Powder and Shower to Shower products.

Medical experts testified that microscopic asbestos fibers enter the body when talcum powder is inhaled or applied to the genital area.  Asbestos fibers and talc particles were found in the ovarian tissues of many of the women.

"For over 40 years, Johnson & Johnson has covered up the evidence of asbestos in their products," said Mr. Lanier. "We hope this verdict will get the attention of the J&J board and that it will lead them to better inform the medical community and the public about the connection between asbestos, talc, and ovarian cancer. The company should pull talc from the market before causing further anguish, harm, and death from a terrible disease. J&J sells the same powders in a marvelously safe corn starch variety. If J&J insists on continuing to sell talc, they should mark it with a serious warning."

Many of the women took the stand at trial to talk about their use of the products and how ovarian cancer affected their quality of life. Six of the plaintiffs have died and were represented at trial by husbands and family members.

In addition to Mr. Lanier, the trial team includes attorneys Lee Cirsch, Rachel Lanier, Dr. Robert Leone, Michael Akselrud, and Monica Cooper of the Lanier Law Firm. Co-counsel Eric D.Holland of the Holland Law Firm in St. Louis, Missouri, was also integrally involved in the trial.

The Lanier Law Firm has offices in Houston, Oklahoma City, New York, and Los Angeles. For close to 30 years, the firm has worked tirelessly to find unique solutions to its clients' unique needs. The firm is composed of more than 60 skilled attorneys, practicing in a broad array of areas, including business fraud, asbestos exposure, commercial litigation, personal injury, oil and gas litigation, among others. Visit http://www.lanierlawfirm.com.

Media Contact:
Barry Pound
(214) 293-0860
[email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/st-louis-jury-returns-4-69-billion-verdict-in-first-trial-linking-baby-powder-asbestos-and-ovarian-cancer-300680511.html

SOURCE Lanier Law Firm

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:Holland,Disease,Cancer,Surgery,Womens Health,Business,Judicial,Family,Other,Women,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Implantable Medical Devices Market Predicted to be Worth US$ 49.8 Bn by 2024, Says TMR
  • Global Cosmetic Chemicals Industry
  • HMP's 8th Annual Amputation Prevention Symposium Expected to Draw 800 Clinicians to Chicago to Join the CLI Revolution
  • Progressive Care Inc. Announces Month-End Sales Figures Showing Increase in Year-Over-Year Prescriptions Filled in June 2018

    Cancer
  • Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder
  • Association of Community Cancer Centers and Advisory Board Launch 9th Annual Trends in Cancer Care Survey
  • Small Animal Imaging Market is Estimated to Grow at a Faster Pace With the Significant CAGR During the Forecast Period: Radiant Insights, Inc.
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines